感染疾病臨床檢驗分子診斷市場:策略與趨勢 - 各用途，場所，各國預測 - 附市場分析和執行顧問指南(2025年～2029年)

感染疾病臨床檢驗分子診斷市場打算完成更變成的成長。市場繼續成長,不過，正在更複雜被細分化做。<傳染病檢查，從生物科技，尤其是基因學的爆炸性的發展受到著直接的恩惠。

本報告提供全球感染疾病按臨床檢驗分子診斷市場相關調查，提供市場概要，以及各用途，場所，各國趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 市場指南

第2章 簡介和市場定義

• 市場定義
• 調查手法
• 觀點:醫療保健費支出
• IVD產品的性質
• 未來的IVD產品

第3章 感染疾病- 病原體的指南

• 感染疾病病原體- 透視
• 冠狀病毒

第4章 產業概要

• 市場進入組織
  • 學術研究機關
  • 診斷測試開發商
  • 測量設備供應商
  • 藥品·試劑廠商
  • 病理供應商
  • 獨立型臨床檢驗室
  • 公共的國立/地區研究所
  • 醫院檢驗室
  • 臨床檢驗室
  • 審核機關
  • 認證機關
• 臨床檢驗市場區隔
• 產業結構

第5章 市場趨勢

• 成長促進因素
• 成長阻礙因素
• 測量，自動化，診斷趨勢

第6章 臨床檢驗MDx感染疾病的最近的趨勢

第7章 主要企業

• Abbott Laboratories
• Agilent
• Altona Diagnostics
• Anitoa
• Autonomous Medical Devices
• Beckman Coulter Diagnostics(Danaher)
• Becton, Dickinson and Company
• BioGX
• Biomatik
• bioMerieux Diagnostics
• Bio-Rad Laboratories, Inc
• Cepheid(Danaher)
• Diasorin S.p.A.
• DNAe
• Flow Health
• Global Access Diagnostics
• Great Basin Scientific, Inc
• Hologic
• Novacyt
• Novus Diagnostics
• Oncimmune
• One Codex
• OraSure Technologies
• Prometheus Laboratories
• Qiagen
• QuidelOrtho
• R-Biopharm AG
• Response Biomedical
• Revvity
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Vela Diagnostics
• Veredus Laboratories
• YD Diagnostics
• Zhejiang Orient Gene Biotech

第8章 全球感染疾病臨床檢驗分子診斷市場

• 各國全球市場概要
• 各用途全球市場- 概要
• 場所全球市場- 概要

第9章 全球感染疾病臨床檢驗分子診斷市場- 各用途

• 呼吸系統
• 血液感染性病毒
• 移植
• 院內感染
• 生殖健康
• C19Singleplex
• 腦膜炎
• 腸胃
• 局部

第10章 按全球感染疾病臨床檢驗分子診斷市場- 場所

• 醫院研究室
• 門診病人檢驗室
• 照護現場
• 其他

第11章 附錄

OVERVIEW:

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report. And find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis

2. Introduction and Market Definition

• 2.1. Market Definition
  • 2.1.1. Market Size
  • 2.1.2. Currency
  • 2.1.3. Years
• 2.2. Methodology
  • 2.2.1. Methodology
  • 2.2.2. Sources
  • 2.2.3. Authors
• 2.3. Perspective: Healthcare Spending
  • 2.3.1. Global Healthcare Spending
  • 2.3.2. Spending on Healthcare and Pharmaceuticals
  • 2.3.3. Spending on Diagnostics
  • 2.3.4. Important Role of Insurance for Medical Services
• 2.4. The Nature of the IVD Product
  • 2.4.1. Features Overview
  • 2.4.2. The Misunderstood Feature
  • 2.4.3. Regulation
  • 2.4.4. The Newest Feature
  • 2.4.5. The Oldest Feature
  • 2.4.6. All About Scope
  • 2.4.7. Why Turnaround is Becoming More Important
  • 2.4.8. The Role of Trust
• 2.5. The IVD Product of the Future

3. Infectious Diseases - Guide to the Pathogens

• 3.1. Infectious Disease Pathogens - The Big Picture
  • 3.1.1. Viruses
  • 3.1.2. Bacteria
  • 3.1.3. Fungi
  • 3.1.4. Parasites
  • 3.1.5. Prions
  • 3.1.6. Virulence
  • 3.1.7. Transmission
• 3.2. The Coronavirus
  • 3.2.1. Severe acute respiratory syndrome (SARS)
  • 3.2.2. Middle East respiratory syndrome (MERS)
  • 3.2.3. COVID-19. The SARS CoV 2 Virus.
    • 3.2.3.1. Signs and symptoms
    • 3.2.3.2. Transmission
    • 3.2.3.3. Diagnosis
    • 3.2.3.4. Prevention
    • 3.2.3.5. Management
    • 3.2.3.6. Prognosis

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Instrumentation Supplier
  • 4.1.4. Chemical/Reagent Supplier
  • 4.1.5. Pathology Supplier
  • 4.1.6. Independent Clinical Laboratory
  • 4.1.7. Public National/regional Laboratory
  • 4.1.8. Hospital Laboratory
  • 4.1.9. Physicians Office Lab (POLS)
  • 4.1.10. Audit Body
  • 4.1.11. Certification Body
• 4.2. The Clinical Laboratory Market Segments
  • 4.2.1. Traditional Market Segmentation
  • 4.2.2. Laboratory Focus and Segmentation
  • 4.2.3. Segmenting the Syndromic Testing Market
• 4.3. Industry Structure
  • 4.3.1. Hospital Testing Share
  • 4.3.2. Economies of Scale
  • 4.3.3. Hospital vs. Central Lab
  • 4.3.4. Physician Office Lab's
  • 4.3.5. Physician's and POCT

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. The Nucleic Acid Impact
  • 5.1.2. Population Dynamics
  • 5.1.3. The Developing World
  • 5.1.4. Decentralization
  • 5.1.5. Self Testing
  • 5.1.6. The Need for Speed
• 5.2. Factors Limiting Growth
  • 5.2.1. Costs and Experience Curve Effects
  • 5.2.2. The Role of ID Prevalence
  • 5.2.3. Wellness
  • 5.2.4. The Impact of Living Standards
• 5.3. Instrumentation, Automation and Diagnostic Trends
  • 5.3.1. Traditional Automation and Centralization
  • 5.3.2. The New Automation, Decentralization and Point Of Care
  • 5.3.3. Instruments Key to Market Share
  • 5.3.4. Bioinformatics Plays a Role
  • 5.3.5. PCR Takes Command
  • 5.3.6. Next Generation Sequencing Fuels a Revolution
  • 5.3.7. NGS Impact on Pricing
  • 5.3.8. Whole Genome Sequencing, A Brave New World
  • 5.3.9. Companion Diagnostics Blurs Diagnosis and Treatment

6. Clinical Laboratory MDx Infectious Disease Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Presymptom Health Nabs Funding for Sepsis Test
• 6.3. FDA Clears BioMerieux GI Panel
• 6.4. Rapid Infection Diagnostic Launches BSIDx
• 6.5. Biotia's AI-, Sequencing-Based UTI Test approved
• 6.6. Delve Bio, Broad Clinical Labs Partner for Metagenomic
• 6.7. Roche Respiratory Panel Receives FDA EUA
• 6.8. Genetic Signatures Gets Approval for GI Parasite Panel
• 6.9. Diasorin Expands Respiratory Panel
• 6.10. BioMerieux Outlines MDx-Driven Growth
• 6.11. T2 Biosystems Gets Extended T2Bacteria Panel
• 6.12. Diasorin Aims to Deliver Updated Instruments, New Assays
• 6.13. Oxford Nanopore Nabs Investment From BioMerieux
• 6.14. Day Zero Diagnostics Closes Financing Round
• 6.15. Spindiag Seeks Investors for Rapid PCR System
• 6.16. Sorrento Therapeutics Nabs Contract for Dx Platform
• 6.17. Kephera Planning Menu of Infectious Disease Tests
• 6.18. Oxford Nanopore and BioMerieux to Develop IDDx
• 6.19. SD Biosensor Eyes Global Expansion
• 6.20. Selux Dx Next Gen Phenotyping Gets FDA Clearance
• 6.21. Takara Developing High-Throughput Multiplex Panels
• 6.22. BioGX Debuts New Point-of-Care Molecular Testing System
• 6.23. Nanopath MDx Platform Providing 15-Minute Results
• 6.24. ProtonDx Commercializing Rapid MDx Instrument
• 6.25. Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
• 6.26. Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
• 6.27. Accelerate Diagnostics Anticipates Growth
• 6.28. Lumos Diagnostics Expanding Test Portfolio
• 6.29. Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens

7. Key Companies

• 7.1. Abbott Laboratories
• 7.2. Agilent
• 7.3. Altona Diagnostics
• 7.4. Anitoa
• 7.5. Autonomous Medical Devices
• 7.6. Beckman Coulter Diagnostics (Danaher)
• 7.7. Becton, Dickinson and Company
• 7.8. BioGX
• 7.9. Biomatik
• 7.10. bioMerieux Diagnostics
• 7.11. Bio-Rad Laboratories, Inc
• 7.12. Cepheid (Danaher)
• 7.13. Diasorin S.p.A.
• 7.14. DNAe
• 7.15. Flow Health
• 7.16. Global Access Diagnostics
• 7.17. Great Basin Scientific, Inc
• 7.18. Hologic
• 7.19. Novacyt
• 7.20. Novus Diagnostics
• 7.21. Oncimmune
• 7.22. One Codex
• 7.23. OraSure Technologies
• 7.24. Prometheus Laboratories
• 7.25. Qiagen
• 7.26. QuidelOrtho
• 7.27. R-Biopharm AG
• 7.28. Response Biomedical
• 7.29. Revvity
• 7.30. Roche Diagnostics
• 7.31. Siemens Healthineers
• 7.32. Thermo Fisher Scientific
• 7.33. Vela Diagnostics
• 7.34. Veredus Laboratories
• 7.35. YD Diagnostics
• 7.36. Zhejiang Orient Gene Biotech

8. The Global Market for Clinical Laboratory MDx Infectious Disease

• 8.1. Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Market by Application - Overview
  • 8.2.1. Table - Global Market by Application
  • 8.2.2. Chart - Global Market by Application - Base/Final Year Comparison
  • 8.2.3. Chart - Global Market by Application - Base Year
  • 8.2.4. Chart - Global Market by Application - End Year
  • 8.2.5. Chart - Global Market by Application - Share by Year
  • 8.2.6. Chart - Global Market by Application - Segments Growth
• 8.3. Global Market by Place - Overview
  • 8.3.1. Table - Global Market by Place
  • 8.3.2. Chart - Global Market by Place - Base/Final Year Comparison
  • 8.3.3. Chart - Global Market by Place - Base Year
  • 8.3.4. Chart - Global Market by Place - End Year
  • 8.3.5. Chart - Global Market by Place - Share by Year
  • 8.3.6. Chart - Global Market by Place - Segments Growth

9. Global Clinical Laboratory MDx Infectious Disease Markets - By Application

• 9.1. Respiratory
  • 9.1.1. Table Respiratory - by Country
  • 9.1.2. Chart - Respiratory Growth
• 9.2. Blood Borne Virus
  • 9.2.1. Table Blood Borne Virus - by Country
  • 9.2.2. Chart - Blood Borne Virus Growth
• 9.3. Transplant
  • 9.3.1. Table Transplant - by Country
  • 9.3.2. Chart - Transplant Growth
• 9.4. Hospital Acquired Infections
  • 9.4.1. Table Hospital Acquired Infections - by Country
  • 9.4.2. Chart - Hospital Acquired Infections Growth
• 9.5. Reproductive Health
  • 9.5.1. Table Reproductive Health - by Country
  • 9.5.2. Chart - Reproductive Health Growth
• 9.6. C19. Singleplex
  • 9.6.1. Table C19 Singleplex - by Country
  • 9.6.2. Chart - C19 Singleplex Growth
• 9.7. Meningitis
  • 9.7.1. Table Meningitis - by Country
  • 9.7.2. Chart - Meningitis Growth
• 9.8. Gastrointestinal
  • 9.8.1. Table Gastrointestinal - by Country
  • 9.8.2. Chart - Gastrointestinal Growth
• 9.9. Tropical
  • 9.9.1. Table Tropical - by Country
  • 9.9.2. Chart - Tropical Growth

10. Global Clinical Laboratory MDx Infectious Disease Markets - By Place

• 10.1. Hospital Lab
  • 10.1.1. Table Hospital Lab - by Country
  • 10.1.2. Chart - Hospital Lab Growth
• 10.2. Outpatient Lab
  • 10.2.1. Table Outpatient Lab - by Country
  • 10.2.2. Chart - Outpatient Lab Growth
• 10.3. Point of Care
  • 10.3.1. Table Point of Care - by Country
  • 10.3.2. Chart - Point of Care Growth
• 10.4. Other Place
  • 10.4.1. Table Other Place - by Country
  • 10.4.2. Chart - Other Place Growth

11. Appendices

• 11.1. Growth of Approved IVD Test Menu
• 11.2. Growth of Approved Average IVD Test Fee
• 11.3. The Most Used IVD Assays
• 11.4. The Highest Grossing Assays
• 11.5. Laboratory Fees Schedule

Table of Tables

• Table 1: Key IVD Features
• Table 2: Features in the Future
• Table 3: Viral Pathogens and Families
• Table 4: Characteristics of Coronavirus Pandemic Infections
• Table 5: COVID-19 Symptoms
• Table 6: Market Players by Type
• Table 7: Clinical Laboratory Departments and Segments
• Table 8: Laboratory Management Focus - Different Approaches
• Table 9: Key Segmentation Variables Going Forward
• Table 10: Possible Market Segments of Syndromic Multiplex Market
• Table 11: Five Factors Driving Growth
• Table 12: Four Factors Limiting Growth
• Table 13: Seven Key Diagnostic Laboratory Technology Trends
• Table 14: Global Market by Region
• Table 15: Global Market by Application
• Table 16: Global Market by Place
• Table 17: Respiratory by Country
• Table 18: Blood Borne Virus by Country
• Table 19: Transplant by Country
• Table 20: Hospital Acquired Infections by Country
• Table 21: Reproductive Health by Country
• Table 22: C19 Singleplex by Country
• Table 23: Meningitis by Country
• Table 24: Gastrointestinal by Country
• Table 25: Tropical by Country
• Table 26: Hospital Lab by Country
• Table 27: Outpatient Lab by Country
• Table 28: Point of Care by Country
• Table 29: Other Place by Country
• Table 30: The Most Common Assays
• Table 31: Largest Revenue Assays
• Table 32: Clinical Lab Fee Schedule

Table of Figures

• Figure 1: Global Healthcare Spending
• Figure 2: Structure of a Typical Virus
• Figure 3: Mycobacterium Tuberculosis
• Figure 4: STRUCTURE OF CORONAVIRUSES
• Figure 5: The Road to Diagnostics
• Figure 6: The Changing Age of The World's Population
• Figure 7: Health Care Consumption by Age
• Figure 8: Cancer Incidence - Age at Diagnosis
• Figure 9: Percentage of World Population Over 65
• Figure 10: Chart Infectious Disease Decline
• Figure 11: Centralized vs. Decentralized Laboratory Service
• Figure 12: A Highly Multiplexed Syndromic Testing Unit
• Figure 13: The Real Cost to Sequence the Human Genome
• Figure 14: The Codevelopment Process
• Figure 15: Global Market Share Chart
• Figure 16: Global Market by Application - Base vs. Final
• Figure 17: Global Market by Application Base Year
• Figure 18: Global Market by Application End Year
• Figure 19: Application Share by Year
• Figure 20: Application Segments Growth
• Figure 21: Global Market by Place - Base vs. Final
• Figure 22: Global Market by Place Base Year
• Figure 23: Global Market by Place End Year
• Figure 24: Place Share by Year
• Figure 25: Place Segments Growth
• Figure 26: Respiratory Growth
• Figure 27: Blood Borne Virus Diagnostics Growth
• Figure 28: Transplant Growth
• Figure 29: Hospital Acquired Infections Growth
• Figure 30: Reproductive Health Growth
• Figure 31: C19 Singleplex Growth
• Figure 32: Meningitis Growth
• Figure 33: Gastrointestinal Growth
• Figure 34: Tropical Growth
• Figure 35: Hospital Lab Growth
• Figure 36: Outpatient Lab Growth
• Figure 37: Point of Care Growth
• Figure 38: Other Place Growth
• Figure 39: IVD Test Menu Growth
• Figure 40: IVD Test Average Fees - A Ten Year View